Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|April 16, 2015
The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevantKobe Reynders, Tim Illidge, Shankar Siva, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology GroupLena Specht, Bouthaina Dabaja, Tim Illidge, et al.
Cancers|November 13, 2013
Molecular targeted agents for gastric cancer: a step forward towards personalized therapyEsther Una Cidon, Sara G Ellis, Yasir Inam, et al.
Cancer Treatment Reviews|July 21, 2015
Obinutuzumab in hematologic malignancies: lessons learned to dateTim Illidge, Christian Klein, Laurie H Sehn, et al.
Haematologica|October 16, 2012
Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK centerAdam Gibb, Craig Jones, Adrian Bloor, et al.
BMC Cancer|November 25, 2021
The effect of hypoxia on PD-L1 expression in bladder cancerVicky Smith, Debayan Mukherjee, Sapna Lunj, et al.
International Journal of Radiation Oncology, Biology, Physics|April 13, 2015
Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology GroupJoachim Yahalom, Tim Illidge, Lena Specht, et al.
Future Oncology (London, England)|December 12, 2025
A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumabTom Geldart, Lisa Pickering, Anand Sharma, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 14, 2011
Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trialLisa Lowry, Paul Smith, Wendi Qian, et al.
European Journal of Haematology|September 27, 2017
Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective studyPaul J Bröckelmann, Erin A Zagadailov, Shelby L Corman, et al.
Pageof 6